Fennec Pharmaceuticals Inc
TSX:FRX
Gross Margin
Fennec Pharmaceuticals Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
F
|
Fennec Pharmaceuticals Inc
NASDAQ:FENC
|
258.7m USD |
90%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.3B USD |
71%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
154.4B USD |
70%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
149.8B USD |
79%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
99.3B USD |
86%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
130.5B AUD |
52%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.4B USD |
86%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
56.3B USD |
84%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
Fennec Pharmaceuticals Inc
Glance View
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Fennec Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 90.3%.
You don't have any saved screeners yet